Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1297 to 1300 of 1300 entries
Sorted by: Best Match Show Resources per page
Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer.

Journal of developmental origins of health and disease

Zhang J, Du M, Sun L.
PMID: 33971999
J Dev Orig Health Dis. 2021 May 11;1-8. doi: 10.1017/S2040174421000234. Epub 2021 May 11.

The effects of supraphysiological estradiol (E2) on neonatal outcomes and the significance of specific E2 concentrations remain unclear. The purpose of this study was to investigate whether supraphysiological E2 levels on the human chorionic gonadotropin (hCG) trigger day are...

Cite
Zhang J, Du M, Sun L. Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer. J Dev Orig Health Dis. 2021;1-8doi: 10.1017/S2040174421000234.
Zhang, J., Du, M., & Sun, L. (2021). Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer. Journal of developmental origins of health and disease, 1-8. https://doi.org/10.1017/S2040174421000234
Zhang, Junwei, et al. "Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer." Journal of developmental origins of health and disease vol. (2021): 1-8. doi: https://doi.org/10.1017/S2040174421000234
Zhang J, Du M, Sun L. Supraphysiological estradiol levels on the hCG trigger day are associated with SGA for singletons born from fresh embryo transfer. J Dev Orig Health Dis. 2021 May 11;1-8. doi: 10.1017/S2040174421000234. Epub 2021 May 11. PMID: 33971999.
Copy Download .nbib Format: NLM
Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer.

European urology oncology

Lobo J, Leão R, Gillis AJM, van den Berg A, Anson-Cartwright L, Atenafu EG, Kuhathaas K, Chung P, Hansen A, Bedard PL, Jewett MAS, Warde P, O'Malley M, Sweet J, Looijenga LHJ, Hamilton RJ.
PMID: 33288479
Eur Urol Oncol. 2021 Jun;4(3):483-491. doi: 10.1016/j.euo.2020.11.004. Epub 2020 Dec 04.

BACKGROUND: Optimal management of clinical stage I (CSI) testicular cancer is controversial due to lack of robust prognostic factors; miRNA-371a-3p holds promise as a biomarker, although its clinical utility for identifying patients at risk of relapse is unknown.OBJECTIVE: To...

Cite
Lobo J, Leão R, Gillis AJM, et al. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol. 2020;4(3):483-491doi: 10.1016/j.euo.2020.11.004.
Lobo, J., Leão, R., Gillis, A. J. M., van den Berg, A., Anson-Cartwright, L., Atenafu, E. G., Kuhathaas, K., Chung, P., Hansen, A., Bedard, P. L., Jewett, M. A. S., Warde, P., O'Malley, M., Sweet, J., Looijenga, L. H. J., & Hamilton, R. J. (2021). Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. European urology oncology, 4(3), 483-491. https://doi.org/10.1016/j.euo.2020.11.004
Lobo, João, et al. "Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer." European urology oncology vol. 4,3 (2021): 483-491. doi: https://doi.org/10.1016/j.euo.2020.11.004
Lobo J, Leão R, Gillis AJM, van den Berg A, Anson-Cartwright L, Atenafu EG, Kuhathaas K, Chung P, Hansen A, Bedard PL, Jewett MAS, Warde P, O'Malley M, Sweet J, Looijenga LHJ, Hamilton RJ. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Eur Urol Oncol. 2021 Jun;4(3):483-491. doi: 10.1016/j.euo.2020.11.004. Epub 2020 Dec 04. PMID: 33288479.
Copy Download .nbib Format: NLM
Unrecognized Primary Hypothyroidism As a Possible Cause of Hyperreactio Luteinalis.

Cureus

Chauhan YV, Dalwadi PP, Gada JV, Varthakavi PK, Bhagwat N.
PMID: 33796422
Cureus. 2021 Feb 26;13(2):e13573. doi: 10.7759/cureus.13573.

Hyperreactio luteinalis (HRL) is characterised by benign enlargement of ovaries in pregnancy associated with hyperandrogenism. A 19-year-old primigravida presented with breathlessness, abdominal distension and vomiting in the thirteenth week of gestation. Abdominal examination revealed distension of abdomen disproportionate to...

Cite
Chauhan YV, Dalwadi PP, Gada JV, et al. Unrecognized Primary Hypothyroidism As a Possible Cause of Hyperreactio Luteinalis. Cureus. 2021;13(2):e13573doi: 10.7759/cureus.13573.
Chauhan, Y. V., Dalwadi, P. P., Gada, J. V., Varthakavi, P. K., & Bhagwat, N. (2021). Unrecognized Primary Hypothyroidism As a Possible Cause of Hyperreactio Luteinalis. Cureus, 13(2), e13573. https://doi.org/10.7759/cureus.13573
Chauhan, Yash V, et al. "Unrecognized Primary Hypothyroidism As a Possible Cause of Hyperreactio Luteinalis." Cureus vol. 13,2 (2021): e13573. doi: https://doi.org/10.7759/cureus.13573
Chauhan YV, Dalwadi PP, Gada JV, Varthakavi PK, Bhagwat N. Unrecognized Primary Hypothyroidism As a Possible Cause of Hyperreactio Luteinalis. Cureus. 2021 Feb 26;13(2):e13573. doi: 10.7759/cureus.13573. PMID: 33796422; PMCID: PMC8005326.
Copy Download .nbib Format: NLM
Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial.

Reproductive sciences (Thousand Oaks, Calif.)

Alexopoulou E, Stormlund S, Løssl K, Prætorius L, Sopa N, Bogstad JW, Mikkelsen AL, Forman J, la Cour Freiesleben N, Vikkelsø Jeppesen J, Bergh C, Al Humaidan PSH, Grøndahl ML, Zedeler A, Pinborg AB.
PMID: 33847977
Reprod Sci. 2021 Oct;28(10):2972-2981. doi: 10.1007/s43032-021-00564-9. Epub 2021 Apr 13.

Gonadotropin-releasing hormone agonist (GnRHa) for final oocyte maturation, along with vitrification of all usable embryos followed by transfer in a subsequent frozen-thawed cycle, is the most effective strategy to avoid ovarian hyperstimulation syndrome (OHSS). However, less is known about...

Cite
Alexopoulou E, Stormlund S, Løssl K, et al. Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial. Reprod Sci. 2021;28(10):2972-2981doi: 10.1007/s43032-021-00564-9.
Alexopoulou, E., Stormlund, S., Løssl, K., Prætorius, L., Sopa, N., Bogstad, J. W., Mikkelsen, A. L., Forman, J., la Cour Freiesleben, N., Vikkelsø Jeppesen, J., Bergh, C., Al Humaidan, P. S. H., Grøndahl, M. L., Zedeler, A., & Pinborg, A. B. (2021). Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial. Reproductive sciences (Thousand Oaks, Calif.), 28(10), 2972-2981. https://doi.org/10.1007/s43032-021-00564-9
Alexopoulou, Evaggelia, et al. "Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial." Reproductive sciences (Thousand Oaks, Calif.) vol. 28,10 (2021): 2972-2981. doi: https://doi.org/10.1007/s43032-021-00564-9
Alexopoulou E, Stormlund S, Løssl K, Prætorius L, Sopa N, Bogstad JW, Mikkelsen AL, Forman J, la Cour Freiesleben N, Vikkelsø Jeppesen J, Bergh C, Al Humaidan PSH, Grøndahl ML, Zedeler A, Pinborg AB. Embryo Morphokinetics and Blastocyst Development After GnRH Agonist versus hCG Triggering in Normo-ovulatory Women: a Secondary Analysis of a Multicenter Randomized Controlled Trial. Reprod Sci. 2021 Oct;28(10):2972-2981. doi: 10.1007/s43032-021-00564-9. Epub 2021 Apr 13. PMID: 33847977.
Copy Download .nbib Format: NLM
Showing 1297 to 1300 of 1300 entries